Pfizer's First-in-Class IL-4/IL-13/TSLP Trispecific Antibody PF-07275315 Granted IND Approval in China for Moderate-to-Severe Asthma

Apr 10, 2025 15:47 CST Updated 15:47

Pfizer

Pharmaceutical R&D Developer

On April 10, the CDE website showed that Pfizer had filed a new drug application for Class 1.PF-07275315 Injection Approved for Clinical Use in China, Intended forAdultModerate to Severe Asthma。

Screenshot source: CDE official website

PF-07275315 is a recombinant tri-specific antibody against IL-4, IL-13, and TSLP. In June 2024, the drug was approved for clinical use in China for the first time.Moderate to Severe Atopic Dermatitis。

In August 2023, Pfizer initiated the first Phase II clinical trial of this drug. This isA Study of PF-07275315 and PF-07264660 in Adult Participants with Moderate to Severe Atopic Dermatitis（IL-4/IL-13/IL-33 Tri-specific Antibody)A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Safety（NCT05995964）. The primary endpoint of the study isEASI-75 at Week 16(Improvement ≥ 75% relative to baseline)。

Insight database shows,PF-07275315 isThe world's first and only IL-4/IL-13/TSLP Trispecific Antibody. Even when looking across the entire trispecific antibody field,The research progress of PF-07275315 is also in a globally leading position, second only to Sanofi's.Sonelokimab(Clinical Phase III)And Roche'sRestoret(Clinical Phase II/III)。

Screenshot source: Insight database

Cover Source:Company Logo

Disclaimer:This article is for information sharing only and does not represent the position or viewpoint of Insight. It also does not recommend or introduce any treatment options. If necessary, please consult and contact正规医疗机构.

Editor：ccai

PR Article Coordination: WeChat insightxb

SubmissionWeChat: insightxb; Email: insight@dxy.cn

Diversified functions, traceable data……

Insight Database Web Version Awaits Your Experience

Click to read the original text,ImmediatelyUnlock！